- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Antigenic Drift Will Not Pose a Problem for NanoViricides' Drugs, says Company
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), presented new preclinical data at the 5th International Bird Flu Conference in Las Vegas on September 28th
( http://www.new-fields.com/birdflu5/viewAgenda.php?newsid=2#day2 ).
Dr. Eugene Seymour, MD, MPH, CEO of the Company, presented results of animal studies of FluCide™-I and FluCide™-HP. "In our completely lethal mouse model, efficacy of FluCide-I has improved significantly, and even FluCide-HP, which is designed against high path influenzas, showed very strong efficacy against H1N1, which was the cause of 1918 Spanish Flu pandemic. The improved FluCide-I is now 16X (1,600%) better than oseltamivir (active ingredient of TamiFlu®), and FluCide-HP is 8X (800%) better than oseltamivir, based on dose-response comparisons." Further, in vitro studies have demonstrated that FluCide-HP is significantly superior to FluCide-I against H5N1, as expected.
In addition to discussing the latest research data, Dr. Seymour compared the various treatment options currently available to the practitioner working on the front lines. "Speakers from Vietnam, Indonesia and Turkey made it clear," said Seymour, that "at the present time, no good treatment options exist. These speakers complained that patients sought medical care too late for Tamiflu® - the drug currently recommended by WHO - to be effective. They also pointed out that resistance to Tamiflu develops quickly. Vaccines may be ineffective in the field due to the antigenic drift caused by the observed rapid mutation rate of the influenza virus, according to these physicians. They fear that antibodies alone also will be ineffective as drugs in the field due to the antigenic drift."
"Mutations and antigenic drift should not allow influenza viruses, even H5N1, to escape FluCide-I," said Dr. Seymour. "Similarly, FluCide-HP attacks the invariant features of the signature region that causes high pathogenicity in avian influenza viruses such as H5N1 and H7N3. If a high path virus learns to evade FluCide-HP, it would have lost this signature, and would therefore no longer be highly pathogenic. Thus it would pose only a minimal threat as a pandemic agent," he added.
"We are now working on the necessary paperwork with an agency to begin animal studies against the highly pathogenic H5N1 virus," he reported.
The Company is also working on nanoviricides against Dengue viruses with the Walter Reed Army Institute of Research. Dengue virus is currently causing the worst outbreak in several years in Latin Americas, and has already crossed the border into the USA
( http://apnews.myway.com/article/20070930/D8RVGI7O0.html ).
About NanoViricides, Inc.
NanoViricides, Inc. ( http://www.nanoviricides.com ) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, dengue fever, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward looking statements are subject to known and unknown risks, uncertainties and other factors including the availability of adequate financing, the success of the Company's research and development strategy, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the “Management’s Discussion and Analysis” section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission. Such risks, uncertainties and other factors may cause actual results, performance, or achievements of the Company to be different from those expressed or implied by the Company.
For more information, please click here
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Leti Announces Launch of First European Nanomedicine Characterisation Laboratory: Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval July 1st, 2015
Nanospiked bacteria are the brightest hard X-ray emitters July 2nd, 2015
Engineering the world’s smallest nanocrystal July 2nd, 2015
Producing spin-entangled electrons July 2nd, 2015